Browse studies

Find your next paid study

26,835 recruiting studies available now

An Incremental Dose Escalation Trial of Safety and Tolerability of Curcumin

The purpose of this study is to see if curcumin can reverse anal high-grade squamous intraepithelial lesions (aHSIL) (high-grade anal precancerous cells or hig…

Anal High Grade Squamous Intraepithelial Lesion

Estimated

~$10 – $7,500

Lisa FlowersNCT06626230

Phase 1

PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

Background: SARS-CoV-2 is the virus that causes COVID-19. Some people who recover from COVID-19 have long-term symptoms that affect the brain. These include h…

Long COVIDPost Acute Sequelae of COVID-19

Estimated

~$10 – $5,625

National Institute of Mental Health (NIMH)NCT06920628

Microbiome Determinants of Adverse Effects of Stereotactic Radiosurgery

This prospective observational study will investigate the relationship between the gut microbiome and adverse effects following stereotactic radiosurgery (SRS)…

Adverse Radiation EffectsRadiation Necrosis

Estimated

~$10 – $750

University of ChicagoNCT07767981

Observational

Electrophysiological Representations of Odor in the Human Brain Study 1

Investigating representations of odor intensity in human piriform cortex. To identify a neural representation of perceived odor intensity, it is necessary to d…

Odor Intensity Ratings

Estimated

~$10 – $6,250

Northwestern UniversityNCT06769464

Phase 1

An Open-label, Single-sequence Multiple Cohort Study to Assess the Effect of Multiple Doses of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on the Pharmacokinetics of Single Doses of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

This study will measure the effects of multiple doses of AZD6234, AZD9550 and a combination of AZD9550 and AZD6234 given as injection(s) on pharmacokinetics (P…

Healthy Participants

Estimated

~$10 – $7,500

AstraZenecaNCT07013643

Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways

Cor360 is an observational study evaluating whether extended wearable electrocardiogram (ECG) data can support broad-spectrum cardiac phenotyping and risk asse…

Cardiovascular DiseasesCardiovascular Diseases RiskCardiac Conduction System Disease+21 more

Estimated

~$10 – $1,050

Peerbridge Health, IncNCT07775976

Phase 1

Phase I/II Trial of Systemic Targeted Radioligand Therapy (TRT) With Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR Positive (SSTR+) Gastrointestinal (GI) Neuroendocrine Tumors (NET) and Pheochromocytoma/Paragangliomas Previously Treated With Systemic Radioligand Therapy

Background: Gastrointestinal neuroendocrine tumors (GI NET) are a type of cancer that affects the stomach and intestines; pheochromocytoma/paragangliomas (PPG…

Somatostatin Receptor PositiveGastrointestinal Neuroendocrine TumorsPheochromocytoma+1 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06427798

Observational

Characterization of an Optically Pumped Magnetometer (OPM) Magnetoencephalography (MEG) Array

Background: Brain activity produces magnetic fields. These fields can be measured outside the head. Existing technology, called MEG, measures these fields. Re…

Normal Physiology

Estimated

~$10 – $5,625

National Institute of Mental Health (NIMH)NCT04950309

Phase 1

A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses

The goal of this clinical trial is to test two investigational COVID-19 booster vaccines, called CoTend-s3BXBB and CoTend-BXBB, in healthy volunteers ages 40-6…

COVID-19SARS-CoV-2 Infection

An Open-Label, International, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Intravesical T3011 Injection in Participants With BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) or BCG-Exposed, Chemotherapy-Unresponsive Intermediate /High-Risk NMIBC

This is a Phase II clinical study to evaluate the efficacy and safety of intravesical T3011 injection in participants with BCG-unresponsive high-risk NMIBC or …

Nonmuscle-invasive Bladder Cancer

Estimated

~$10 – $8,750

ImmVira Pharma Co. LtdNCT06971614

Phase 1

A Phase 1/2a, First-in-human, Randomized, Double-blinded, Placebo-controlled, Dose-finding Study in Healthy Volunteers and Participants With Sickle Cell Disease to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, pH and Food Effect, and Preliminary Efficacy of BMS-986470

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BM…

Anemia, Sickle CellHealthy Volunteers

Estimated

~$10 – $7,500

Bristol-Myers SquibbNCT06481306

Phase 1

A Randomized Controlled Pilot Study of Two Doses of Cord Blood Tissue-Derived Mesenchymal Stromal Cells Combined With Ruxolitinib Versus Ruxolitinib Alone for Therapy of Steroid-Refractory Acute Graft Versus Host Disease

This early phase I trial is to find out the effect of adding cord blood tissue-derived mesenchymal stromal cells (cb-MSCs) to ruxolitinib in treating patients …

Hematopoietic and Lymphoid Cell NeoplasmSteroid Refractory Graft Versus Host Disease

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT04744116